Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2016; 22(48): 10502-10511
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10502
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10502
Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research
Trond A Buanes, Department of Hepato-Pancreatico-Biliary Surgery, Oslo University Hospital, N-0424 Oslo, Norway
Trond A Buanes, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0424 Oslo, Norway
Author contributions: Buanes TA solely contributed to this manuscript.
Conflict-of-interest statement: The author has no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Trond A Buanes, MD, PhD, Professor of Surgery, Department of Hepato-Pancreatico-Biliary Surgery, Oslo University Hospital, Nydalen, N-0424 Oslo, Norway. trond.buanes@medisin.uio.no
Telephone: +47-23070958 Fax: +47-23072526
Received: August 15, 2016
Peer-review started: August 16, 2016
First decision: October 11, 2016
Revised: October 14, 2016
Accepted: November 23, 2016
Article in press: November 28, 2016
Published online: December 28, 2016
Peer-review started: August 16, 2016
First decision: October 11, 2016
Revised: October 14, 2016
Accepted: November 23, 2016
Article in press: November 28, 2016
Published online: December 28, 2016
Core Tip
Core tip: More effective chemotherapy and reorganized care for patients with periampullary carcinoma has opened windows of opportunity for improved surgical performance. Combined with neoadjuvant and adjuvant chemotherapy new patient groups can therefore be offered potentially curative treatment. A biomarkers can predict gemcitabine sensitivity, thus improving patient selection. A three-biomarker panel in urine can identify patients with early pancreatic adenocarcinoma. Clinical implementation of new diagnostic and therapeutic options is mandatory.